The N-oxide of anti-psychotic drug Blonanserin (BLNO) was synthesized and tested as a novel molecule to understand its ability in
reducing blood glucose levels.
Identification of risk factors for obstructive sleep apnea (OSA) is important to enable comprehensive intervention to reduce OSA-related cardiovascular disease (CVD). The metabolic syndrome outcome study (MetSO) provides a unique opportunity to address these factors. This study investigated risk of OSA among blacks with metabolic syndrome.